Universal Sequencing Technology Corporation Launches High-Throughput Solution For Microbial WGS Library Preparation

By: Universal Sequencing Technology Corporation

CARLSBAD, Calif. – Mar 14, 2023 -- Universal Sequencing Technology Corporation (UST), a global leader in genomic sequencing innovations, announced today the release of a high throughput microbial WGS library preparation kit enabling 2nd-generation short-read sequencers to produce long-range results in a much affordable price for microbial genomes.

With this special high throughput kit, users can pool more microbial samples in one sequencing run in combination with our 96-well plate multiplexing primers, which includes 10-base indexes and significantly reduces NGS library preparation and sequencing costs.

Researchers will now be able to take advantage of the ultra-long linked-read results to provide unparalleled genomic information with up to 200Kb gDNA fragments for microbial genome analyses.

With TELL-Seq technology, we've made NGS library preparation easy. Our products effectively improve performance, process time, and budget across a broad range of sample types with a proven track record.

Dr. Tom Chen, Chief Scientific Officer of UST, stated, "We are further streamlining the TELL-seq workflow with reduced cost per reaction and expanded throughput in response to increased customer demands."

UST's TELL-Seq is a patent-pending transposase-based linked-read library preparation technology that enables short-read 2nd generation DNA sequencing platforms, such as Illumina sequencers, to produce long-range sequencing results (averaging linked-read molecule length greater than 40kb and up to 200kb). With a simple workflow, a sequencing-ready Illumina library can be prepared in PCR tubes in about 3 hours, cost-effective and no special lab equipment needed.

ABOUT UST

Universal Sequencing Technology Corporation (UST), a Boston and San Diego-based NGS biotechnology company, was established by a group of NGS veterans. UST is dedicated to developing the most advanced DNA sequencing technologies and has filed more than 20 PCT patent applications covering linked read NGS library preparation, single-cell sequencing, and groundbreaking 3rd-generation DNA sequencing technologies. UST is poised to lead the next wave of DNA sequencing innovations.

www.universalsequencing.com

Universal Sequencing Technology Corporation (UST) partners with TATAA Biocenter to offer Long Read Sequencing Services with TELL-Seq Linked-Read Technology in Europe

By: Universal Sequencing Technology Corporation

Universal Sequencing Technology Corporation (UST) announces today, January 10th, 2023, that it has partnered with TATAA Biocenter, one of our key distributors in Europe, to offer full-service solutions for Long Read Sequencing Applications using UST TELL-Seq Linked Read technology.

TATAA Biocenter was founded in 2001 and is a leading provider of molecular services to the Advanced Therapies and Medical products (ATMP) industries in Europe and the Cell and Gene Therapy industry in the United States.

UST’s TELL-Seq technology, a transposase-based patent-pending linked-read library technology, enables short read 2nd generation NGS platforms, such as Illumina sequencers, to produce super long-range sequencing results (averaging linked-read molecule length greater than 40kb, up to and exceeding 200kb). A sequencing-ready library can be prepared in a PCR tube in ~3 hours with a simple workflow and basic lab equipment, which is simple, fast, and cost-effective. A unique feature of UST TELL-Seq is that it only requires ultra-low DNA input, 3-5ng for the human genome and 0.1-0.5ng for microbial genomes and target sequencing panels.

Dr. Aaron U. Levy, GM & Chief Commercial Officer of UST, who recently visited the TATAA Biocenter facility in Gothenburg, stated that he was impressed with the laboratory’s setup, corporate culture, professionalism, and up-to-code superb sequencing services. Levy added that “TELL-Seq library technology is compatible with the range of Illumina sequencing platforms from benchtop like MiniSeq™ up to high-throughput NovaSeq™ 6000. The collaboration between UST and TATAA, based on the growing need for long-read results with very accurate short-read Illumina sequencers, is speeding up the adoption of UST’s super long-range TELL-Seq NGS library products among Illumina users in the US and all over the world.”

With UST TELL-Seq library preparation kits and an Illumina sequencer, one can do de novo sequencing of microbial, animal, plant, and insect genomes, metagenomics, human genome phasing, and structural variation detection.

Mikael Kubista, the founder and CEO of TATAA Biocenter, stated, “The innovative TELL-Seq Linked-Read Technology for long-read sequencing is a most welcome complement to our service offerings. Our customers and sponsors will now gain additional advantages over their competitors through our broad range of qualified molecular services.”

ABOUT TATAA BIOCENTER

TATAA Biocenter is a leading provider of molecular services to the Advanced Therapies and Medical products (ATMP) industry in Europe and the Cell and Gene Therapy industry in the United States. With ISO 17025 accreditation and Good Laboratory and Clinical Practices

(GLP/GCP) ready facility TATAA is perfectly positioned to support the pharmaceutical industry with biomarker profiling, including genomics, transcriptomics, and proteomics with traditional qPCR, dPCR, and NGS methods, as well as proprietary methods.

ABOUT UNIVERSAL SEQUENCING TECHNOLOGY CORPORATION

Universal Sequencing Technology Corporation (UST), a Boston and San Diego-based NGS biotechnology company, was established by a group of NGS veterans. UST is dedicated to developing the most advanced DNA sequencing technologies and has filed more than 20 provisional patent applications covering linked read NGS library preparation, single-cell sequencing, and groundbreaking 3rd generation DNA sequencing technologies. UST is poised to lead the next wave of DNA sequencing innovations.

Universal Sequencing Technology Corporation Announces High-Throughput Solution For NGS Library Preparation

UST releases high-throughput solution enabling second-generation short-read sequencers to produce long-range results in greater capacity.

CARLSBAD, Calif.-Oct. 24, 2022-PRLog Universal Sequencing Technology Corporation (UST), a global leader in genomic sequencing innovations, announces today, October 24th, 2022, the release of 96-well plate TELL-Seq™ Library Multiplexing Primers for high throughput sample indexing.

With this expanded indexing capability, our customers/TELL-seq users can pool many samples in one sequencing run, significantly reducing NGS library preparation and sequencing costs. The 96-well plate multiplexing primers include the 10-base indexes that will ensure their compatibility across different Illumina sequencing platforms providing the most stringent nucleotide balance in each sequencing cycle to achieve the optimal performance and highest sequencing quality. The 10-base index primers come in a 96-well plate format with a pierceable seal, making their use with NGS library preparation automation platforms convenient and easy.

When used in combination with the UST's TELL-Seq High Throughput kit, researchers will be able to take advantage of the ultra-long linked-read results to provide unparalleled genomic information up to and exceeding 200Kb gDNA fragments with applications ranging from WGS, phasing, SV detection, metagenomics, and more for small, medium, and large genomes.

With TELL-Seq NGS technology, we've made library preparation easy. Our products effectively improve performance, time, and budget across a broad range of sample types with a proven track record.

Dr. Zhoutao (Tom) Chen, Chief Scientific Officer of UST, stated, "We are further streamlining the TELL-seq workflow by simplifying sample preparation and scaling up throughput in response to increased customer demands."

UST's TELL-Seq is a patent-pending transposase-based linked-read library preparation technology that enables short-read 2nd generation DNA sequencing platforms, such as Illumina sequencers, to produce long-range sequencing results (averaging linked-read molecule length greater than 40kb up to and exceeding 200kb). With a simple workflow, a sequencing-ready library can be prepared in PCR tubes in about 3 hours, cost-effectively, and with minimal lab equipment.

Dr. Aaron U. Levy, GM & Chief Commercial Officer of UST, stated, "TELL-Seq Linked-Long-Read Library technology provides valuable solutions that enrich the short read sequencers by enabling them to produce the long-range results ranging to 200kb and more."

  

Universal Sequencing Technology Corporation Announces “TELL-Seq Haplotype Phasing” App Launched on Illumina Basespace

CARLSBAD, Calif.-Aug. 2, 2022-PRLog-- Universal Sequencing Technology Corporation (UST), announces today, August 2nd, 2022, that it has released "TELL-Seq Haplotype Phasing" App on Illumina Basespace™ Sequence Hub to further streamline and enable access to the TELL-Seq haplotype phasing workflow solution. This can effectively be used in broad research areas including genetic disease research, HLA haplotyping, complex variant linkage, and trait analysis.

UST's TELL-Seq technology, a transposase-based patent-pending linked-read library technology, enables short read 2ndgeneration DNA sequencing platforms, such as Illumina sequencers, to produce super long-range sequencing results (averaging linked-read molecule length greater than 40kb up to and exceeding 200kb).  Sequencing ready libraries can be prepared quickly in ~3 hours, with a simple workflow, and cost effectively with only basic lab equipment.

Dr. Aaron U. Levy, GM & Chief Commercial Officer of UST, stated that "TELL-Seq library technology is compatible with the range of Illumina sequencing platforms from benchtop like MiniSeq™ up to high-throughput NovaSeq™ 6000. The collaboration between UST and Illumina, based on the co-development and co-marketing agreement signed early 2021, is speeding up the adoption of UST's super long range TELL-Seq NGS library products among Illumina users, in the US and all over the world."

Dr. Dalia Daujotyte, Director of NGS Partnerships and Applications at Illumina, stated that "TELL-Seq linked read technology provides valuable solutions that enrich the Illumina  ecosystem and we have been pleased to partner with UST."

To demonstrate the capabilities of the TELL-Seq phasing workflow and new BSSH app, UST and Illumina have co-developed and released the application note "Ultra-long range phasing with linked-read sequencing technology."By combining highly accurate Illumina sequencing and UST TELL-Seq library technology the app note demonstrates excellent haplotype phasing performance and enables users to generate phasing block greater than >10Mb and libraries with N50 phasing blocks >1Mb with human whole genome when utilizing high molecular weight input DNA.

It has been demonstrated that TELL-Seq can phase the entire 4Mb major histocompatibility complex (MHC) region into two complete parental haplotypes (Chenet al, Genome Res. 2020 Jun;30(6):898-909.doi: 10.1101/gr.260380,119). MHC region contains many highly polymorphic HLA genes which play a critical role in organ transplantation and are associated with many diseases.

According to Dr. Zhoutao (Tom) Chen, Chief Scientific Officer of UST, "With super long-range TELL-Seq library kit and an Illumina sequencer, one can now perform de novo sequencing (microbial genomes, metagenomics, animals/plants/insects, etc.), whole genome phasing, and structural variation detection, as well as generate phased whole exome and target sequencing.  Unique to this technology, it requires very low input DNA, 3-5ng for large genomes (>2Gb) and 0.1-0.5ng for small genomes (<10Mb) and targeted gene panels."

A recent Nature Medicine article (Kumaret al. Nat Med28, 513–516, 2022.https://doi.org/10.1038/s41591-022-01735-0) demonstrated superior TELL-Seq phasing results to detect phased rare variants with high accuracy for whole-genome risk prediction of common diseases in human preimplantation embryos.  In addition to genome-scale phasing application, TELL-Seq has been used successfully in targeted phasing applications, such as, phased whole exome sequencing, phasing enriched full length gene targets, e.g., 200kb BRCA1 and BRCA2 genes, and phasing 2kb to 15kb long-range PCR amplicons.

Dr. Ming Lei, Co-Founder and CEO of UST also added that " we are continuing to advance our technology and expand our product pipeline into multiple NGS application areas that require super long read. We will continue to partner with Illumina to support further expansion of Illumina sequencing platforms' applications, based on our co-development, co-marketing, and commercial agreement."